Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 151-163

  Ma, Di ^a   Cao, Weifeng ^a   Kapur, Arvinder ^b   Felder, Mildred ^b   Scarlett, Cameron O ^a   Patankar, Manish S ^b   Li, Lingjun ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

IL 2 signaling; Lab free quantification; Mass spectrometry pathways; Multi dimensional separation; NK cells; Proteomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; INTERLEUKIN 2; PLATELET DERIVED GROWTH FACTOR; PROTEOME; UBIQUITIN;

ARTICLE; CELL LYSATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; WNT SIGNALING PATHWAY;

IL-2 SIGNALING; LAB-FREE QUANTIFICATION; MASS SPECTROMETRY PATHWAYS; MULTI-DIMENSIONAL SEPARATION; NK CELLS; PROTEOMICS;

ANTIGENS, CD; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; INTEGRINS; INTERLEUKIN-2; KILLER CELLS, NATURAL; PLATELET-DERIVED GROWTH FACTOR; PROTEOME; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UBIQUITIN; WNT PROTEINS;

EID: 84881525417     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.06.024     Document Type: Article

References (72)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
2. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
3. Smith K.A. Interleukin-2: inception, impact, and implications. Science 1988, 240:1169-1176.
4. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990, 171:1509-1526.
5. Bonnema J.D., Rivlin K.A., Ting A.T., Schoon R.A., Abraham R.T., Leibson P.J. Cytokine-enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis. J Immunol 1994, 152:2098-2104.
6. Karnitz L.M., Abraham R.T. Interleukin-2 receptor signaling mechanisms. Adv Immunol 1996, 61:147-199.
7. Russell S.M., Johnston J.A., Noguchi M., Kawamura M., Bacon C.M., Friedmann M., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994, 266:1042-1045.
8. Ellery J.M., Nicholls P.J. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 2002, 13:27-40.
9. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994, 370:151-153.
10. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv Immunol 1998, 70:1-81.
11. Frank D.A., Robertson M.J., Bonni A., Ritz J., Greenberg M.E. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A 1995, 92:7779-7783.
12. Garcia-Lora A., Martinez M., Pedrinaci S., Garrido F. Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother 2003, 52:59-64.
13. Yu T.K., Caudell E.G., Smid C., Grimm E.A. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 2000, 164:6244-6251.
14. Zhou J., Zhang J., Lichtenheld M.G., Meadows G.G. A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling. J Immunol 2002, 169:1319-1325.
15. Ussat S., Scherer G., Fazio J., Beetz S., Kabelitz D., Adam-Klages S. Human NK cells require caspases for activation-induced proliferation and cytokine release but not for cytotoxicity. Scand J Immunol 2010, 72:388-395.
16. Smith F.O., Downey S.G., Klapper J.A., Yang J.C., Sherry R.M., Royal R.E., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14:5610-5618.
17. Klapper J.A., Downey S.G., Smith F.O., Yang J.C., Hughes M.S., Kammula U.S., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113:293-301.
18. Buhtoiarov I.N., Neal Z.C., Gan J., Buhtoiarova T.N., Patankar M.S., Gubbels J.A., et al. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol 2011, 89:625-638.
19. Delgado D.C., Hank J.A., Kolesar J., Lorentzen D., Gan J., Seo S., et al. Genotypes of NK cell KIR receptors, their ligands, and Fc gamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010, 70:9554-9561.
20. Gubbels J.A., Gadbaw B., Buhtoiarov I.N., Horibata S., Kapur A.K., Patel D., et al. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother 2012, 60:1789-1800.
21. Yang R.K., Kalogriopoulos N.A., Rakhmilevich A.L., Ranheim E.A., Seo S., Kim K., et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol 2012, 189:2656-2664.
22. Lund T.C., Anderson L.B., McCullar V., Higgins L., Yun G.H., Grzywacz B., et al. iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types. J Proteome Res 2007, 6:644-653.
23. Man P., Novak P., Cebecauer M., Horvath O., Fiserova A., Havlicek V., et al. Mass spectrometric analysis of the glycosphingolipid-enriched microdomains of rat natural killer cells. Proteomics 2005, 5:113-122.
24. Hanna J., Fitchett J., Rowe T., Daniels M., Heller M., Gonen-Gross T., et al. Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol 2005, 42:425-431.
25. Hanna J., Gonen-Gross T., Fitchett J., Rowe T., Daniels M., Arnon T.I., et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004, 114:1612-1623.
26. Casey T.M., Meade J.L., Hewitt E.W. Organelle proteomics: identification of the exocytic machinery associated with the natural killer cell secretory lysosome. Mol Cell Proteomics 2007, 6:767-780.
27. Gubbels J.A., Felder M., Horibata S., Belisle J.A., Kapur A., Holden H., et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010, 9:11.
28. Belisle J.A., Gubbels J.A., Raphael C.A., Migneault M., Rancourt C., Connor J.P., et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007, 122:418-429.
29. Patankar M.S., Jing Y., Morrison J.C., Belisle J.A., Lattanzio F.A., Deng Y., et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 2005, 99:704-713.
30. Song C., Ye M., Han G., Jiang X., Wang F., Yu Z., et al. Reversed-phase-reversed-phase liquid chromatography approach with high orthogonality for multidimensional separation of phosphopeptides. Anal Chem 2010, 82:53-56.
31. Brosch M., Yu L., Hubbard T., Choudhary J. Accurate and sensitive peptide identification with Mascot Percolator. J Proteome Res 2009, 8:3176-3181.
32. Zhang Y., Wen Z., Washburn M.P., Florens L. Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. Anal Chem 2010, 82:2272-2281.
33. Zybailov B., Mosley A.L., Sardiu M.E., Coleman M.K., Florens L., Washburn M.P. Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. J Proteome Res 2006, 5:2339-2347.
34. Schmidt H., Gelhaus C., Nebendahl M., Lettau M., Watzl C., Kabelitz D., et al. 2-D DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells. Proteomics 2008, 8:2911-2925.
35. Gilar M., Olivova P., Daly A.E., Gebler J.C. Orthogonality of separation in two-dimensional liquid chromatography. Anal Chem 2005, 77:6426-6434.
36. Strader M.B., Tabb D.L., Hervey W.J., Pan C., Hurst G.B. Efficient and specific trypsin digestion of microgram to nanogram quantities of proteins in organic-aqueous solvent systems. Anal Chem 2006, 78:125-134.
37. Wang K.S., Ritz J., Frank D.A. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol 1999, 162:299-304.
38. Wang K.S., Frank D.A., Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 2000, 95:3183-3190.
39. Koyama S. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma. J Cancer Res Clin Oncol 1997, 123:478-484.
40. Gollob J.A., Mier J.W., Veenstra K., McDermott D.F., Clancy D., Clancy M., et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000, 6:1678-1692.
41. Andersen J.N., Mortensen O.H., Peters G.H., Drake P.G., Iversen L.F., Olsen O.H., et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 2001, 21:7117-7136.
42. Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J. The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr Biol 2002, 12:446-453.
43. Myers M.P., Andersen J.N., Cheng A., Tremblay M.L., Horvath C.M., Parisien J.P., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001, 276:47771-47774.
44. Aoki N., Matsuda T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 2000, 275:39718-39726.
45. Kurki P., Lotz M., Ogata K., Tan E.M. Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol 1987, 138:4114-4120.
46. Bohler T., Nolting J., Kamar N., Gurragchaa P., Reisener K., Glander P., et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 2007, 29:77-86.
47. Barten M.J., Tarnok A., Garbade J., Bittner H.B., Dhein S., Mohr F.W., et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007, 40:50-63.
48. Millan O., Benitez C., Guillen D., Lopez A., Rimola A., Sanchez-Fueyo A., et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 2010, 137:337-346.
49. Niwa M., Miwa Y., Kuzuya T., Iwasaki K., Haneda M., Ueki T., et al. Stimulation index for PCNA mRNA in peripheral blood as immune function monitoring after renal transplantation. Transplantation 2009, 87:1411-1414.
50. Rosental B., Brusilovsky M., Hadad U., Oz D., Appel M.Y., Afergan F., et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 2011, 187:5693-5702.
51. Rosental B., Hadad U., Brusilovsky M., Campbell K.S., Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. Oncoimmunology 2012, 1:572-574.
52. Boles K.S., Stepp S.E., Bennett M., Kumar V., Mathew P.A. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 2001, 181:234-249.
53. Vaidya S.V., Stepp S.E., McNerney M.E., Lee J.K., Bennett M., Lee K.M., et al. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol 2005, 174:800-807.
54. Kim E.O., Kim T.J., Kim N., Kim S.T., Kumar V., Lee K.M. Homotypic cell to cell cross-talk among human natural killer cells reveals differential and overlapping roles of 2B4 and CD2. J Biol Chem 2010, 285:41755-41764.
55. Sinha S.K., Gao N., Guo Y., Yuan D. Mechanism of induction of NK activation by 2B4 (CD244) via its cognate ligand. J Immunol 2010, 185:5205-5210.
56. Gray J.X., Haino M., Roth M.J., Maguire J.E., Jensen P.N., Yarme A., et al. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 1996, 157:5438-5447.
57. Kop E.N., Matmati M., Pouwels W., Leclercq G., Tak P.P., Hamann J. Differential expression of CD97 on human lymphocyte subsets and limited effect of CD97 antibodies on allogeneic T-cell stimulation. Immunol Lett 2009, 123:160-168.
58. Haynes B.F., Hemler M.E., Mann D.L., Eisenbarth G.S., Shelhamer J., Mostowski H.S., et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981, 126:1409-1414.
59. Moretta A., Mingari M.C., Haynes B.F., Sekaly R.P., Moretta L., Fauci A.S. Phenotypic characterization of human cytolytic T lymphocytes in mixed lymphocyte culture. J Exp Med 1981, 153:213-218.
60. Yan Y., Vasudevan S., Nguyen H.T., Merlin D. Intestinal epithelial CD98: an oligomeric and multifunctional protein. Biochim Biophys Acta 2008, 1780:1087-1092.
61. Deves R., Boyd C.A. Surface antigen CD98(4F2): not a single membrane protein, but a family of proteins with multiple functions. J Membr Biol 2000, 173:165-177.
62. Warren A.P., Patel K., Miyamoto Y., Wygant J.N., Woodside D.G., McIntyre B.W. Convergence between CD98 and integrin-mediated T-lymphocyte co-stimulation. Immunology 2000, 99:62-68.
63. Miyamoto Y.J., Mitchell J.S., McIntyre B.W. Physical association and functional interaction between beta1 integrin and CD98 on human T lymphocytes. Mol Immunol 2003, 39:739-751.
64. Cantoni C., Bottino C., Augugliaro R., Morelli L., Marcenaro E., Castriconi R., et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 1999, 29:3148-3159.
65. Ju X., Zenke M., Hart D.N., Clark G.J. CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 2008, 112:1184-1194.
66. Clark G.J., Rao M., Ju X., Hart D.N. Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression. J Leukoc Biol 2007, 82:1126-1135.
67. Alvarez Y., Tang X., Coligan J.E., Borrego F. The CD300a (IRp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Mol Immunol 2008, 45:253-258.
68. Nakahashi-Oda C., Tahara-Hanaoka S., Honda S., Shibuya K., Shibuya A. Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. Biochem Biophys Res Commun 2012, 417:646-650.
69. Deblandre G.A., Marinx O.P., Evans S.S., Majjaj S., Leo O., Caput D., et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem 1995, 270:23860-23866.
70. Friedman R.L., Manly S.P., McMahon M., Kerr I.M., Stark G.R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984, 38:745-755.
71. Yang G., Xu Y., Chen X., Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007, 26:594-603.
72. Di Santo J.P. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006, 24:257-286.